HEPTA MEDICAL, a medical technology company developing a minimally invasive treatment for early-stage lung cancer, announced the closing of its €10 million oversubscribed Series A financing round.
The round welcomes Ul Investissement and Supernova Invest as new investors, alongside existing shareholders Bpifrance, M&L, Cléry and MD Start, reinforcing the company’s financial capacity as it prepares to launch its clinical trials.
Related: Mediwhale secures $13.1M in Series C funding, preparing for IPO
HEPTA MEDICAL’s develops a minimally invasive thermal ablation treatment delivered through the airway to treat early-stage lung cancer. The company’s technology integrates proprietary sensors capable of monitoring treatment progression in real time, allowing physicians to track the growth of the ablation zone during the procedure.
This SERIES A will enable HEPTA MEDICAL accelerate its clinical execution, strengthen its industrial readiness, and prepare for future regulatory milestones.
Lung cancer remains one of the most common and deadliest cancers worldwide. As countries deploy and expand lung cancer screening programs, notably with low-dose CT, more patients are identified at an earlier stage, when curative approaches may be possible.
This shift increases the need for safe, scalable, and efficient early-stage lung cancer management, helping reduce delays in care and improving patient outcomes. HEPTA MEDICAL is building a solution designed to support this evolution of care by enabling precise, minimally invasive intervention and real-time monitoring during treatment.
As part of this new phase of development, Jérôme Edwards, co-founder of Veran (acquired by Olympus) and CEO of CardioNXT, joins HEPTA MEDICAL’s Board as an independent member.
“We are grateful for the continued trust of our existing investors, and excited to welcome Ul Investissement and Supernova Invest. With our minimally invasive airway-based thermal ablation platform, we aim to deliver a step change in how early-stage lung cancer can be managed.” — Thomas Bancel, CEO of HEPTA MEDICAL
“With screening programs expanding, the demand for scalable solutions to manage early-stage lung cancer patients at lower cost and with improved clinical control compared to current approaches such as stereotactic radiotherapy (SRBT) and surgery is growing rapidly. HEPTA MEDICAL’s technology combines a minimally invasive approach with real-time monitoring, which we believe can become highly relevant to future care pathways. Through its healthcare fund Majycc Innovation Santé, Ul Investissement is proud to support the company as it enters clinical trials.” — Tanguy Besson, Ul Investissement
“The expansion of lung cancer screening is fundamentally changing how early-stage disease will be managed.
HEPTA MEDICAL combines a minimally invasive approach with real-time monitoring capabilities, offering the potential to significantly improve treatment precision and scalability. We are proud to support the team as they advance clinical validation and move toward clinical adoption” — Pascal André Chenal, Supernova Invest
“I’m delighted to join HEPTA MEDICAL’s Board as an independent member at this important inflection point. HEPTA is tackling a clear unmet need with a compelling technology approach-minimally invasive therapy delivered through the airway, with real-time sensing to monitor treatment progression, building a strong parallel with what has happened in Interventional Cardiology in the last 20 years. I look forward to supporting the company’s governance and execution as it progresses into clinical trials and prepares for broader adoption.” — Jérôme Edwards, Independent Board Member
